Bluejay Diagnostics Inc Stock Price, News & Analysis

Bluejay Diagnostics (NASDAQ: BJDX) announced its financial results for Q1 2022, reporting a cash position of $17.1 million. This is down from $19.0 million at the end of 2021, but expected to support operations until the anticipated regulatory approval and launch of its Symphony IL-6 Test. The company saw a substantial rise in R&D expenses to $695,000 from $24,000 year-over-year, reflecting ongoing clinical studies. Net loss for the quarter was $2.0 million, or $0.10 per share, compared to $194,000, or $0.06 per share in Q1 2021.

Bluejay Diagnostics, Inc. (NASDAQ: BJDX) has appointed Edwin “Ed” E. Rule as Vice President of Regulatory, Quality, and Compliance. With over 15 years of experience in medical device regulations, Mr. Rule is expected to enhance the company's efforts towards its Symphony IL-6 Test marketing application to the FDA due later this year. The Symphony System aims to provide rapid, near-patient diagnostic testing to improve patient outcomes in critical care settings.

Mr. Rule's expertise will be pivotal in navigating regulatory processes and ensuring product compliance.

Bluejay Diagnostics, Inc. (NASDAQ: BJDX) announced the appointment of Kenneth Fisher as the new Chief Financial Officer (CFO), effective March 23, 2022, following the resignation of Gordon Kinder. Fisher, a Certified Public Accountant with over 20 years of experience, previously held senior executive positions in public accounting and finance. His role will focus on enhancing financial and operational infrastructure as the company advances its Symphony Test for IL-6 through regulatory processes toward commercial launch. Fisher expressed enthusiasm for contributing to the company's mission of improving patient outcomes.

Bluejay Diagnostics (NASDAQ: BJDX) reported Q4 and full-year 2021 financial results, highlighting a significant increase in cash to approximately $19 million, enabling operations beyond anticipated FDA approval for the Symphony IL-6 Test. The company is progressing towards its FDA Marketing Application planned for Q3 2022 and has initiated a comprehensive clinical testing program for the IL-6 Test in sepsis triage. Bluejay's net loss expanded to $3.49 million for 2021, up from $1.16 million in 2020, largely due to increased R&D and administrative costs.

Bluejay Diagnostics, Inc. (NASDAQ: BJDX) announced the successful filing of a Pre-Submission package for its Symphony IL-6 Test with the FDA. This filing aims to gather feedback before a formal marketing application, expected in Q3 2022. The Symphony IL-6 Test is designed to rapidly measure IL-6 levels in whole blood, assisting healthcare professionals in treating patients with severe diseases. Bluejay is developing this user-friendly testing system to provide results in approximately 24 minutes, enhancing patient care in critical settings.

Bluejay Diagnostics (NASDAQ: BJDX) announced the completion of a multicenter clinical study involving 90 subjects focused on a rapid IL-6 test for COVID-19 patients in critical care. Conducted at three hospitals in Dallas, Texas, this study validates the use of unprocessed whole blood for IL-6 measurement, positioning Bluejay for forthcoming FDA submissions. The Symphony System aims to provide quicker test results, essential for triaging patients. Bluejay plans to file a Pre-Submission application with the FDA by January 2022 and commence expanded clinical testing, with results supporting a 510(k) marketing application in Q3:22.

Bluejay Diagnostics (BJDX) has appointed Dr. Mark W. Feinberg as Chief Medical Advisor to lead clinical development programs. Dr. Feinberg, a specialist in cardiovascular medicine, will guide the advancement of the Symphony IL-6 Test, which aims to improve sepsis triage and monitoring. The company plans to file its FDA Pre-Submission application in January 2022 and expects to start expanded clinical testing in Q3 2022. The Symphony System is designed for rapid near-patient testing, delivering results in about 24 minutes.

Bluejay Diagnostics, Inc. (NASDAQ: BJDX) announced a successful $21.6 million IPO and progress on its IL-6 test for sepsis triage. The company initiated clinical testing in October 2021, with a planned FDA Pre-Submission filing in January 2022. Following positive steps, Bluejay aims to expand testing and file a 510(k) marketing application by Q3 2022. Financial results show a net loss of $1.19 million for Q3 2021, up from $128,000 in Q3 2020, with R&D expenses significantly increasing due to clinical trial preparations. Cash and equivalents rose to $2.33 million by September 30, 2021.

Bluejay Diagnostics, Inc. (NASDAQ: BJDX) announced the pricing of its Initial Public Offering (IPO) of 2,160,000 units at $10.00 each, generating gross proceeds of approximately $21.6 million. Each unit comprises one share of common stock, one Class A warrant, and one Class B warrant, with specific exercise prices and conditions. The offering includes a 45-day option for underwriters to purchase additional shares and warrants. The shares will trade under the ticker BJDX starting November 10, 2021. The funds will support the development of the IL-6 Sepsis triage product and general corporate purposes.